ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT AUGUST 2026

Zinzino reported August group revenue of SEK 282.2 million, up 15% year over year (vs. SEK 245.9 million), with sales markets revenue rising 16% to SEK 280.9 million. For January–August 2026, cumulative revenue increased 22% to SEK 2,464.8 million (from SEK 2,027.8 million). Faun Pharma external sales were SEK 1.3 million in August, down from SEK 3.4 million.

Analysis

The signal is more about operating momentum than immediate earnings power. For ZNZNF, sustained double-digit sales growth typically supports multiple expansion only if it translates into distributor productivity and not just more spending on incentives; the market will likely give credit for now, but the burden of proof is on gross margin and cash conversion in the next 1-2 quarters. If revenue acceleration is broad-based across geographies, it strengthens the case that the platform is still in an early penetration phase rather than maturing into a promo-driven treadmill.

The second-order issue is the manufacturing layer. PHMMF’s weak external sales are not a core equity story by themselves, but they may imply the asset is increasingly captive to the group, which can improve supply assurance and reduce third-party dependency while making standalone demand less relevant. That matters because any capacity bottleneck, inventory build, or quality issue would show up first in service levels and then in SG&A efficiency, not in the top line.

Competitively, this kind of update is most harmful to smaller wellness/direct-selling peers that rely on similar recruiting economics, especially if Zinzino is gaining share without a big step-up in marketing intensity. The contrarian risk is that investors overread monthly revenue prints in a business where channel fill, timing, and geography can distort the run rate; if the next quarter shows margin pressure or slowing sequential growth, the market may compress the premium quickly. Near-term reversal would likely come from a weak Q3 gross margin print, rising inventory days, or any sign that growth is being purchased rather than organically generated.

Key Decisions for Investors

• Hold/accumulate ZNZNF only on pullbacks, not on strength; this is a momentum-confirmation trade with a 1-3 month horizon, but require next update to show growth without margin dilution before adding size.
• Watch-list pair: long ZNZNF vs short HLF or USNA if you want relative exposure to better channel momentum; thesis works only if Zinzino keeps compounding revenue while peers remain flat-to-low single digit.
• Avoid leaning on PHMMF as a standalone long until there is evidence the captive manufacturing mix improves utilization or margins; current data is too thin to justify paying for the external sales line.
• Set a falsifier on ZNZNF: if the next quarterly report shows revenue growth decelerating below low-double digits or gross margin slipping materially, treat the move as channel noise and fade the premium.
• If you need expression with limited downside, use a small call-spread position in ZNZNF for the next 1-2 earnings cycles rather than outright equity, since the main risk is valuation compression if operating leverage fails to show up.